Genetic Data Predicts LDL Cholesterol Response to Statins
By LabMedica International staff writers Posted on 15 Oct 2014 |
Genomic data could predict whether statins will benefit a patient or not, and this data alone can explain around 15% of patients' responses to a low density lipoprotein cholesterol (LDLC) lowering drugs.
Statins are used to try to lower patients' levels of cholesterol, a type of fat which is carried in the blood and can block arteries. While they reduce rates of heart disease in many patients, clinicians have debated whether they should be prescribed widely, because they have significant side-effects which some argue outweigh the benefits.
Scientists at Children's Hospital Oakland Research Institute (Oakland, CA, USA) studied 372 participants in an American clinical trial for the statin, Simvastatin. Fasting plasma was collected at two pre-treatment time points (screening visit and enrollment visit) and at two post-treatment time points (four and six weeks of treatment). Because LDLC levels were not significantly different between screening and enrollment, the average of these two measurements was used as the pretreatment LDLC value to minimize technical variation. For the same reason, the average of four and six week measurements was used as the post-treatment LDLC value.
Gene expression levels were measured using the Human-Ref8v3 beadarray (Illumina; San Diego, CA, USA) in 480 lymphoblastoid cell lines (LCLs) derived from Caucasian American participants in the study. Genotyping was performed on 304 samples with Illumina’s HumanHap300 or 208 samples on Illumina’s HumanHap610-Quad BeadChips. Expression levels of each gene were then quantile normalized, adjusted for known covariates, date, ribonucleic acid (RNA) labeling batch, beadarray hybridization batch, and gender and quantile normalized again.
The scientists found that found that differences in around 100 genes could explain 12% to 17% of the variation in how effectively the statin lowered patients' LDL-cholesterol. The genes were particularly accurate in predicting the patients that responded very well or very poorly to the treatment. Some of these genes were involved in cholesterol metabolism, but further studies are needed to find out about the function of the others.
The authors concluded that transcriptomic information can explain a substantial proportion of the variance in LDLC response to statin treatment, and suggest that this may provide a framework for identifying novel pathways that influence cholesterol metabolism. The study was published on September 30, 2014, in the journal Genome Biology.
Related Links:
Children's Hospital Oakland Research Institute
Illumina
Statins are used to try to lower patients' levels of cholesterol, a type of fat which is carried in the blood and can block arteries. While they reduce rates of heart disease in many patients, clinicians have debated whether they should be prescribed widely, because they have significant side-effects which some argue outweigh the benefits.
Scientists at Children's Hospital Oakland Research Institute (Oakland, CA, USA) studied 372 participants in an American clinical trial for the statin, Simvastatin. Fasting plasma was collected at two pre-treatment time points (screening visit and enrollment visit) and at two post-treatment time points (four and six weeks of treatment). Because LDLC levels were not significantly different between screening and enrollment, the average of these two measurements was used as the pretreatment LDLC value to minimize technical variation. For the same reason, the average of four and six week measurements was used as the post-treatment LDLC value.
Gene expression levels were measured using the Human-Ref8v3 beadarray (Illumina; San Diego, CA, USA) in 480 lymphoblastoid cell lines (LCLs) derived from Caucasian American participants in the study. Genotyping was performed on 304 samples with Illumina’s HumanHap300 or 208 samples on Illumina’s HumanHap610-Quad BeadChips. Expression levels of each gene were then quantile normalized, adjusted for known covariates, date, ribonucleic acid (RNA) labeling batch, beadarray hybridization batch, and gender and quantile normalized again.
The scientists found that found that differences in around 100 genes could explain 12% to 17% of the variation in how effectively the statin lowered patients' LDL-cholesterol. The genes were particularly accurate in predicting the patients that responded very well or very poorly to the treatment. Some of these genes were involved in cholesterol metabolism, but further studies are needed to find out about the function of the others.
The authors concluded that transcriptomic information can explain a substantial proportion of the variance in LDLC response to statin treatment, and suggest that this may provide a framework for identifying novel pathways that influence cholesterol metabolism. The study was published on September 30, 2014, in the journal Genome Biology.
Related Links:
Children's Hospital Oakland Research Institute
Illumina
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans